The H2S prodrug SG-1002 has been evaluated in a phase I clinical trial [ID: NCT01989208] in healthy and heart failure subjects, showing attenuation in the increases in BNP in heart failure patients [504], but it is not used in the treatment of heart failure patients because of its lack of a stable, controllable H2S booster [505]. This evidence concerns the gene NPPB and heart failure.